Kawasaki disease in children

Heart

Volumn 95, Issue 10, 2009, Pages 787-792

  Wood, L E ^a   Tulloh, R M R ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR; CYCLOSPORIN; DIPYRIDAMOLE; DOBUTAMINE; EMOLLIENT AGENT; FIBRINOGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE; METHOTREXATE; METHYLPREDNISOLONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPERANTIGEN; TACROLIMUS; TECHNETIUM 99M; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; GENETIC POLYMORPHISM; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAGNETIC RESONANCE ANGIOGRAPHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STRESS ECHOCARDIOGRAPHY; THROMBOSIS;

CHILD; CHILD, PRESCHOOL; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY THROMBOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NITRIC OXIDE; POLYMORPHISM, GENETIC;

EID: 66149143954     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.143669     Document Type: Review

References (83)

1. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967;16:178-222.
2. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin North Am 1995;42:1205-1222
3. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics 2000;106:E27.
4. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005;47:232-234
5. Levin M, Tizard EJ, Dillon MJ. Kawasaki disease: recent advances. Arch Dis Child 1991;66:1369-1372
6. Cimaz R, Falcini F. An update on Kawasaki disease. Autoimmun Rev 2003;2:258-263 (Pubitemid 37083492)
7. Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. Pediatrics 1989;84:666-669 (Pubitemid 19237567)
8. Breunis WB, Biezeveld MH, Geissler J, et al. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol 2007;150:83-90. (Pubitemid 47383291)
9. Nishimura S, Zaitsu M, Hara M, et al. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 2003;143:357-362 (Pubitemid 37188321)
10. Oh JH, Han JW, Lee SJ, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol 2005;29:402-
11. Onouchi Y, Onoue S, Tamari M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004;12:1062-1068 (Pubitemid 39600134)
12. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008;40:35-42.
13. Brogan PA, Shah V, Bagga A, et al. T cell Vbeta repertoires in childhood vasculitides. Clin Exp Immunol 2003;131:517-527 (Pubitemid 36324144)
14. Leung DY, Sullivan KE, Brown-Whitehorn TF, et al. Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr Res 1997;42:268-272 (Pubitemid 27362720)
15. Leung DY, Meissner C, Fulton D, et al. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J Clin Immunol 1995;15(Suppl):11S-7S.
16. Burns JC, Cayan DR, Tong G, et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology 2005;16:220-225 (Pubitemid 40314415)
17. Han RK, Sinclair B, Newman A, et al. Recognition and management of Kawasaki disease. CMAJ 2000;162:807-812 (Pubitemid 30171598)
18. Bronstein DE, Dille AN, Austin JP, et al. Relationship of climate, ethnicity and socioeconomic status to Kawasaki disease in San Diego County, 1994 through 1998. Pediatr Infect Dis J 2000;19:1087-1091
19. Burgner D, Harnden A. Kawasaki disease: What is the epidemiology telling us about the etiology? Int J Infect Dis 2005;9:185-194
20. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191:499-502. (Pubitemid 40216663)
21. Gupta-Malhotra M, Rao PS. Current perspectives on Kawasaki disease. Indian J Pediatr 2005;72:621-629 (Pubitemid 41178992)
22. Rowley AH, Baker SC, Shulman ST, et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004;190:856-865 (Pubitemid 39050018)
23. Rowley AH, Shulman ST. New developments in the search for the etiologic agent of Kawasaki disease. Curr Opin Pediatr 2007;19:71-74 (Pubitemid 46114761)
24. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child 2002;86:286-290 (Pubitemid 34289632)
25. Tizard JE. Recognition and management of Kawasaki disease. Curr Paediatr 1999;8:97-101.
26. Witt MT, Minich LL, Bohnsack JF, et al. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999;104:e10.
27. Carlton-Conway D, Ahluwalia R, Henry L, et al. Behaviour sequelae following acute Kawasaki disease. BMC Pediatr 2005;5:14. (Pubitemid 41418293)
28. Sundel RP. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 2002;4:474-482
29. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-1733 (Pubitemid 41754943)
30. Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007;49:421-426 (Pubitemid 46961850)
31. Fukushige J, Takahashi N, Ueda Y, et al. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994;83:1057-1060 (Pubitemid 24335775)
32. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-1639
33. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-893 (Pubitemid 28027615)
34. Lang B, Duffy CM. Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 2002;16:427-442 (Pubitemid 36526653)
35. Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-1061
36. Freeman AF, Shulman ST. Recent developments in Kawasaki disease. Curr Opin Infect Dis 2001;14:357-361 (Pubitemid 32493549)
37. Gedalia A. Kawasaki disease: an update. Curr Rheumatol Rep 2002;4:25-29
38. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211-217 (Pubitemid 32640933)
39. Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999;135:411-413 (Pubitemid 30180466)
40. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-675 (Pubitemid 46257229)
41. Lee MS, An SY, Jang GC, et al. A case of intravenous immunoglobulin- resistant Kawasaki disease treated with methotrexate. Yonsei Med J 2002;43:527-532
42. Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001;10:1279-1289 (Pubitemid 32633570)
43. Etheridge SP, Tani LY, Minich LL, et al. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease. Cathet Cardiovasc Diagn 1998;45:264-268 (Pubitemid 28503339)
44. Williams RV, Wilke VM, Tani LY, et al. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002;109:E4.
45. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-264 (Pubitemid 38657183)
46. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-6301
47. Ahn SY, Jang GC, Shin JS, et al. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med J 2003;44:1021-1026 (Pubitemid 38081569)
48. Bacon PA. Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol 2005;17:49-55. (Pubitemid 40075647)
49. Shen CT, Wang NK. Antioxidants may mitigate the deterioration of coronary arteritis in patients with Kawasaki disease unresponsive to high-dose intravenous gamma-globulin. Pediatr Cardiol 2001;22:419-422 (Pubitemid 32802497)
50. Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 2000;181:1101-1109 (Pubitemid 30194498)
51. Hirose K, Nakamura Y, Yanagawa H. Cardiac sequelae of Kawasaki disease in Japan over 10 years. Acta Paediatr Jpn 1995;37:667-671 (Pubitemid 26018728)
52. Lu CP, Lee WJ, Ho MM, et al. Risk factors of coronary arterial aneurysm in Kawasaki disease. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1993;34:173-180
53. Honkanen VE, McCrindle BW, Laxer RM, et al. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003;24:122-126 (Pubitemid 36920031)
54. Zhang T, Yanagawa H, Oki I, et al. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr 2002;91:517-520 (Pubitemid 34620637)
55. Tulloh RM, Wood LE. Coronary artery changes in patients with Kawasaki disease. Acta Paediatr Suppl 2004;93:75-79 (Pubitemid 39664533)
56. Rowley AH. The etiology of Kawasaki disease: superantigen or conventional antigen? Pediatr Infect Dis J 1999;18:69-70.
57. Hsueh KC, Lin YJ, Chang JS, et al. Association of vascular endothelial growth factor C-634 G polymorphism in Taiwanese children with Kawasaki disease. Pediatr Cardiol 2008;29:292-296
58. Wilson N, Heaton P, Calder L, et al. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience. J Paediatr Child Health 2004;40:524-529 (Pubitemid 39387546)
59. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int 2004;46:590-596 (Pubitemid 39423208)
60. Vanlieferinghen PH, Brunet F, Beaufrere AM, et al. [Sudden unexpected death in an infant due to a ruptured coronary aneurysm revealing Kawasaki disease.] Arch Pediatr 2002;9:1248-1251
61. Hunsaker DM, Hunsaker JC 3rd, Adams KC, et al. Fatal Kawasaki disease due to coronary aneurysm rupture with massive cardiac tamponade. J Ky Med Assoc 2003;101:233-238
62. Takahashi K, Oharaseki T, Naoe S, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005;47:305-310 (Pubitemid 40827508)
63. Terai M, Yasukawa K, Honda T, et al. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr Infect Dis J 2002;21:777-781
64. Samada K, Igarashi H, Shiraishi H, et al. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease. Eur J Pediatr 2002;161:538-541
65. Gavin PJ, Crawford SE, Shulman ST, et al. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003;23:576-581 (Pubitemid 36438068)
66. Ikemoto Y. Nitric oxide in Kawasaki disease. J Pediatr 2003;142:594-5; author reply 595-596
67. Adewuya O, Irie Y, Bian K, et al. Mechanism of vasculitis and aneurysms in Kawasaki disease: role of nitric oxide. Nitric Oxide 2003;8:15-25. (Pubitemid 36263428)
68. Khajoee V, Kariyazono H, Ohno T, et al. Inducible and endothelial constitutive nitric oxide synthase gene polymorphisms in Kawasaki disease. Pediatr Int 2003;45:130-134 (Pubitemid 36578928)
69. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-1385
70. Checchia PA, Pahl E, Shaddy RE, et al. Cardiac transplantation for Kawasaki disease. Pediatrics 1997;100:695-699 (Pubitemid 27425996)
71. Kato H, Inoue O, Kawasaki T, et al. Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 1992;340:1127-1129
72. Zilberman MV, Goya G, Witt SA, et al. Dobutamine stress echocardiography in the evaluation of young patients with Kawasaki disease. Pediatr Cardiol 2003;24:338-343 (Pubitemid 37021433)
73. Kanamaru H, Karasawa K, Ichikawa R, et al. [Advantages of multislice spiral computed tomography for evaluation of serious coronary complications after Kawasaki disease.] J Cardiol 2007;50:21-27
74. Fukuda T, Ishibashi M, Yokoyama T, et al. Myocardial ischemia in Kawasaki disease: evaluation with dipyridamole stress technetium 99m tetrofosmin scintigraphy. J Nucl Cardiol 2002;9:632-637 (Pubitemid 36050210)
75. Hiraishi S, Hirota H, Horiguchi Y, et al. Transthoracic Doppler assessment of coronary flow velocity reserve in children with Kawasaki disease: comparison with coronary angiography and thallium-201 imaging. J Am Coll Cardiol 2002;40:1816-1824 (Pubitemid 35341961)
76. Noto N, Karasawa K, Kanamaru H, et al. Non-invasive measurement of coronary flow reserve in children with Kawasaki disease. Heart 2002;87:559-565 (Pubitemid 34547983)
77. Harada K, Yasuoka K, Tamura M, et al. Coronary flow reserve assessment by Doppler echocardiography in children with and without congenital heart defect: comparison with invasive technique. J Am Soc Echocardiogr 2002;15(Pt 2):1121-1126 (Pubitemid 36528713)
78. Mavrogeni S, Papadopoulos G, Douskou M, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004;43:649-652 (Pubitemid 38229539)
79. Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with Kawasaki disease. Circulation 2002;105:908-911 (Pubitemid 34184565)
80. Danias PG, Stuber M, Botnar RM, et al. Coronary MR angiography clinical applications and potential for imaging coronary artery disease. Magn Reson Imaging Clin N Am 2003;11:81-99. (Pubitemid 36384076)
81. Schratz LM, Meyer RA, Schwartz DC. Serial intracoronary ultrasound in children: feasibility, reproducibility, limitations, and safety. J Am Soc Echocardiogr 2002;15:782-790
82. Ishii M, Ueno T, Ikeda H, et al. Sequential follow-up results of catheter intervention for coronary artery lesions after Kawasaki disease: quantitative coronary artery angiography and intravascular ultrasound imaging study. Circulation 2002;105:3004-3010 (Pubitemid 34693834)
83. Yamauchi H, Ochi M, Fujii M, et al. Optimal time of surgical treatment for Kawasaki coronary artery disease. J Nippon Med Sch 2004;71:279-286 (Pubitemid 39263671)